Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFNX Pfenex	$12.75	$0.00	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
PLI ProMetic Life Sciences		C$13.60	C$7.13 ▼ C$590.00	C$317.06M	N/A	8,002 shs	921 shs
RVX Resverlogix	C$0.06	C$0.06	C$0.05 ▼ C$0.17	C$14.97M	0.78	38,143 shs	15,000 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PLI ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
RVX Resverlogix	0.00%	0.00%	-8.33%	-21.43%	-67.65%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLI ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFNX Pfenex	N/A	N/A	N/A	N/A
PLI ProMetic Life Sciences	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A
PLI ProMetic Life Sciences	C$39.91M	0.00	N/A	3.94	C$6.07 per share	0.00
RVX Resverlogix	N/A	N/A	C$0.00 per share	132.50	C($0.26) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFNX Pfenex	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PLI ProMetic Life Sciences	N/A	-C$63.06	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	-C$12.82M	-C$0.05	N/A	∞	N/A	N/A	N/A	-37.10%	5/9/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A
PLI ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFNX Pfenex	N/A	N/A	N/A
PLI ProMetic Life Sciences	37.47	4.06	3.66
RVX Resverlogix	N/A	0.11	0.04

Ownership

Institutional Ownership

Company	Institutional Ownership
PFNX Pfenex	N/A
PLI ProMetic Life Sciences	N/A
RVX Resverlogix	N/A

Insider Ownership

Company	Insider Ownership
PFNX Pfenex	N/A
PLI ProMetic Life Sciences	N/A
RVX Resverlogix	43.19%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable
PLI ProMetic Life Sciences	487	23.31 million	N/A	Not Optionable
RVX Resverlogix	19	272.17 million	N/A	Not Optionable

PLI, PFNX, and RVX Headlines

Source	Headline
	Resverlogix Announces Change to Its Board of Directors finance.yahoo.com - February 21 at 8:02 PM
	Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits finance.yahoo.com - January 11 at 10:03 AM
	Closing Bell: Resverlogix Corp flat on Tuesday (RVX) theglobeandmail.com - January 4 at 6:16 PM
	Resverlogix Corp. (RVX) Earnings Dates & Reports investing.com - December 19 at 7:28 PM
	Resverlogix Corp RVXCF morningstar.com - November 18 at 5:49 PM
	Resverlogix Corp RVX morningstar.com - November 1 at 11:18 AM
	Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX) theglobeandmail.com - October 18 at 7:46 AM
	Resverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finanznachrichten.de - October 4 at 10:11 AM
	Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finance.yahoo.com - October 4 at 10:11 AM
	Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight finance.yahoo.com - September 26 at 8:50 PM
	Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes finance.yahoo.com - August 29 at 10:13 AM
	Closing Bell: Resverlogix Corp up on Wednesday (RVX) theglobeandmail.com - August 24 at 3:35 PM
	Closing Bell: Resverlogix Corp flat on Monday (RVX) theglobeandmail.com - August 14 at 10:02 PM
	Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A) theglobeandmail.com - July 12 at 7:21 AM
	Resverlogix Announces Warrant Repricing and One-Year Extension finance.yahoo.com - June 29 at 11:09 PM
	Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finanznachrichten.de - June 20 at 7:31 PM
	Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finance.yahoo.com - June 20 at 7:31 PM
	Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients finance.yahoo.com - June 12 at 6:42 PM
	Canadian Investment Regulatory Organization Trading Halt - RVX.WT.A finance.yahoo.com - June 7 at 1:32 PM
	Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A) theglobeandmail.com - June 6 at 10:49 AM
	Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A) theglobeandmail.com - May 25 at 12:52 AM
	CBOE RUSSELL 2000 VOLATILITY IN (^RVX) finance.yahoo.com - May 18 at 12:38 AM
	Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz news.google.com - May 13 at 3:47 PM
	Resverlogix : MD&A Q1 2023 - Marketscreener.com news.google.com - May 12 at 3:50 PM

Media Sentiment Over Time

Top Headlines

Delta Airline’s Put Option Activity Isn’t Bad News
March 28, 2024 8:55 AM
View Delta Airline’s Put Option Activity Isn’t Bad News
Chipotle Stock Shoots Higher, Announcing 50 for 1 Stock Split
March 20, 2024 10:26 AM
View Chipotle Stock Shoots Higher, Announcing 50 for 1 Stock Split
WD-40 Company Greases the Wheels of Growth and Profits
April 10, 2024 10:12 AM
View WD-40 Company Greases the Wheels of Growth and Profits
Cannabis: One Stock to Play the Movement
April 8, 2024 8:38 AM
View Cannabis: One Stock to Play the Movement
SMART Global Gets 25% Discount: Analysts Lift Targets
April 11, 2024 10:21 AM
View SMART Global Gets 25% Discount: Analysts Lift Targets

All Headlines

Company Descriptions

Pfenex

NYSEAMERICAN:PFNX

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

ProMetic Life Sciences

TSE:PLI

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Resverlogix

TSE:RVX

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial